Management of Respiratory Syncytial Virus Infections

  • John Mills
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)

Abstract

Almost from the time of its discovery nearly 4 decades ago in chimpanzees and humans with respiratory infections, respiratory syncytial virus (RSV) was appreciated as a major cause of serious lower respiratory disease in young children.1 However, despite intensive research in many laboratories, epidemics of RSV continue to occur unchecked throughout the world. Although ribavirin has been used to treat RSV disease for over a decade, its efficacy and the indications for its administration remain controversial. However, recent studies suggest that immunotherapeutic and immunoprophylactic strategies may ultimately lead to control of RSV infections.

Keywords

Respiratory Syncytial Virus Respiratory Syncytial Virus Infection Human Respiratory Syncytial Virus Respiratory Syncytial Virus Disease Respiratory Syncytial Virus Season 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hall CB, McCarthy CA. “Respiratory syncytial virus”, Chapter 136 in Mandell GL, Bennett JE, Dolin R, Editors, Principles and Practice of Infectious Diseases, 4th Edition, Churchill Livingstone, New York 1995, p. 1501–18.Google Scholar
  2. 2.
    Englund JA, Sullivan CJ, Jordan MC, et al. Respiratory syncytial virus infection in immunocompromised adults. Ann Int Med 1988; 109: 203–208.PubMedCrossRefGoogle Scholar
  3. 3.
    Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992; 165: 987–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Pohl C. Green M, Wald ER, et al. Respiratory syncytial virus infections in pediatric liver transplant recipients. J Infect Dis 1991; 165: 166–9.CrossRefGoogle Scholar
  5. 5.
    Hertz MI, Englund JA, Snover D, et al. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: A clinical approach and review of the literature. Medicine 1989; 68: 269–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Whimbey E, Couch R, Englund J, et al. Respiratory syncytial virus (RSV) pneumonia among hospitalized adult patients with leukemia. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 1994. Abstract H84.Google Scholar
  7. 7.
    King JC, Burke AR, Clemens JD, et al. Respiratory syncytial virus illnesses in human immunodeficiency virus-and noninfected children. Pediatr Infect Dis J 1993; 12: 733–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Chandwani S, Barkowsky W, Krasinski K, et al. Respiratory syncytial virus infection in human immunodeficiency virus-infected children. J Pediatr 1990; 117: 251–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Groothuis JR, Salbenblatt CK, Lauer BA. Severe respiratory syncytial virus infection in older children. Am J Dis Children 1990; 144: 348.Google Scholar
  10. 10.
    Mathur U, Bentley DW, Hall CB. Concurrent respiratory syncytial virus and influenza A infections in the instititutionalized elderly and chronically ill. Ann Int Med 1980; 93: 49–52.PubMedCrossRefGoogle Scholar
  11. 11.
    Takimoto CH, Cram Dl, Root RK. Respiratory syncytial virus infections on an adult medical ward. Arch Intern Med 1991; 15: 706–8.CrossRefGoogle Scholar
  12. 12.
    Agius G, Dindinaud G, Biggar RJ, et al. An epidemic of respiratory syncytial virus in elderly people: Clinical and serological findings. J Med Virol 1990; 30: 117–27.PubMedCrossRefGoogle Scholar
  13. 13.
    Guidry GG, Black-Payne CA, Payne DK, et al. Respiratory syncytial virus infection among intubated adults in a university medical intensive care unit. Chest 1991; 100: 1377–84.PubMedCrossRefGoogle Scholar
  14. 14.
    Gilbert BE, Knight V. Overview of ribavirin, selenazole and derivatives. In Mills J, Corey L, editors, Antiviral Chemotherapy, New Directions for Clinical Application and Research. Elsevier, New York, 1986. p63–74.Google Scholar
  15. 15.
    Toltzis P. The mechanism of action of ribavirin. Ibid, 74–77.Google Scholar
  16. 16.
    McIntosh K. Chemotherapy of respiratory syncytial virus infections. Ibid, 83–88.Google Scholar
  17. 17.
    Hayden FG Update on antiviral chemotherapy of respiratory viral infections. In Mills J, Corey L, editors, Antiviral Chemotherapy, New Directions for Clinical Application and Research, vol 2. Elsevier, New York, 1989. p117–142.Google Scholar
  18. 18.
    Hayden FG. Antiviral agents (ribavirin). In Mandell GL, Bennett JE, Dolin R, Editors, Principles and Practice of Infectious Diseases, 4th Edition, Churchill Livingstone, New York 1995, p430–31.Google Scholar
  19. 19.
    Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983; 308: 1443–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Hall CB, McBride JT, Gala CL, et al. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA 1985; 254: 3047–3051.PubMedCrossRefGoogle Scholar
  21. 21.
    Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991; 325: 24.PubMedCrossRefGoogle Scholar
  22. 22.
    Meert KL, Sarnaik AP, Gelmini MJ, et al. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: A prospective, double-blind, randomized trial. Crit Care Med 1994; 22: 566.PubMedCrossRefGoogle Scholar
  23. 23.
    England JA, Piedra PA, Ahn YM, et al. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Ped 1994; 125: 635–41.CrossRefGoogle Scholar
  24. 24.
    Wheeler JG, Wofford J, Turner MS, et al. Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection. Pediatr Infect Dis J 1993; 12: 209–13.PubMedCrossRefGoogle Scholar
  25. 25.
    Treanor JJ. Viral infections of the respiratory tract: prevention and treatment. Int J Antimicrob Agents 1994; 4: 1–22.PubMedCrossRefGoogle Scholar
  26. 26.
    Chipps BE, Sullivan WF, Portnoy JM. Alpha-2A-interferon for treatment of bronchiolitis by respiratory syncytial virus. Pediatr Infect Dis J 1993; 12: 663–8.Google Scholar
  27. 27.
    Groothuis JR, Simoes EAF. Immunoprophylaxis and immunotherapy: role in the prevention and treatment of respiratory syncytial virus. Int J Antimicrob Agents 1993; 2: 97–104.PubMedCrossRefGoogle Scholar
  28. 28.
    Rimensburger PC, Schaad UB. Clinical experience with aerosolized immunoglobulin treatment of RSV infection in infants. Pediatr Inf Dis 1994; 13: 328–30.CrossRefGoogle Scholar
  29. 29.
    Englund JA. Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody. [Review]. Pediatr Infect Dis J 1994; 13: 449–53.PubMedCrossRefGoogle Scholar
  30. 30.
    Garcia O, Martin M, Dopazo J, et al. Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein. J Virol 1994; 68: 5448–5459.PubMedGoogle Scholar
  31. 31.
    Taylor G, Stott EJ, Bew M, et al. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunol 1984; 52: 137.Google Scholar
  32. 32.
    Walsh EE, Schlesinger JJ, Brandriss MW, et al. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun 1984; 43: 756–758.PubMedGoogle Scholar
  33. 33.
    Chanock RM, Parrott RH, Connors M, et al. Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatr 1992; 90: 137.Google Scholar
  34. 34.
    Hall CB. Prospects for a respiratory syncytial virus vaccine. [Review]. Science 1994; 265: 1393.PubMedCrossRefGoogle Scholar
  35. 35.
    Hall CB, Walsh EE, Long CE,et al. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991; 163: 693–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Lamprecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 1976; 134: 211.PubMedCrossRefGoogle Scholar
  37. 37.
    Levin MJ. Treatment and prevention options for respiratory sync, virus infections. J Pediatr 1994; 124: 522 - S27.Google Scholar
  38. 38.
    Piazza FM, Johnson SA, Ottolini MG, et al. Lmmunotherapy of respiratory syncytial virus infection in cotton rats (Sigmodon fulviventer) using IgG in a small-particle aerosol. J Infect Dis 1992; 166: 1422–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Prince GA, Hemming VG, Horswood RL, et al. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol 1987; 61: 1851–1854.PubMedGoogle Scholar
  40. 40.
    Crowe JE, Murphy BR, Chanock RM, et al. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci 1994; 91: 1386–1390PubMedCrossRefGoogle Scholar
  41. 41.
    Weltzin R, Hsu SA, Mittlev ES, et al. Intranasal IgA against RSV protects against upper and lower respiratory tract infections in mice. Antimicrob Ag Chemother 1994; 38: 2785–91.CrossRefGoogle Scholar
  42. 42.
    Hemming VG, Rodriguez W, Kim HW, et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young childrén. Antimicrob Ag Chemother 1987; 31: 1882–1886.CrossRefGoogle Scholar
  43. 43.
    Taylor G, Furze J. Tempest PR, et al. Humanised monoclonal antibody to respiratory syncytial virus. Lancet 1991; 337: 1411–1412.PubMedCrossRefGoogle Scholar
  44. 44.
    Rimensberger PC, Schaad UB. Clinical experience with aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Pediatr Infect Dis J 1994; 13: 328.PubMedCrossRefGoogle Scholar
  45. 45.
    Siber GR, Leszcynski J, Pena CV. et al. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis 1992; 165: 456–63.PubMedCrossRefGoogle Scholar
  46. 46.
    Meissner HC, Fulton DR, Groothuis J, et al. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Ag Chemother 1993; 37: 1655–8.CrossRefGoogle Scholar
  47. 47.
    Groothius JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993; 329: 1524–30.CrossRefGoogle Scholar
  48. 48.
    Murphy BR, Hall SL, Kulkarni AB, et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. [Review]_ Virus Res 1994; 32: 13.PubMedGoogle Scholar
  49. 49.
    Oien, NL, Brideau RJ, Thomsen DR, et al. Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity. Vaccine 1993; 11: 1040.PubMedCrossRefGoogle Scholar
  50. 50.
    Crowe JEJ, Collins PL, London WT, et al. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 1993;11:1395–1404_Google Scholar
  51. 51.
    Crowe JJ, Bui PT, London WT, et al. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 1994; 12: 691.PubMedCrossRefGoogle Scholar
  52. 52.
    Hsu KH, Lubeck MD, Bhat BM, et al. Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model. Vaccine 1994; 12: 607.PubMedCrossRefGoogle Scholar
  53. 53.
    Kakut TJ, Soike K, Brideau RT, et al. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis 1993; 167: 553–61.CrossRefGoogle Scholar
  54. 54.
    Hildreth SW, Baggs RR, Brownstein DG, et al. Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3–6 months after immunization. Vaccine 1993; 11: 615.PubMedCrossRefGoogle Scholar
  55. 55.
    Tristram DA, Welliver RC, Mahar CK, et al. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18–36 months old. J Infect Dis 1993; 167: 191–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Paradiso PR, Hildreth SW, Hogerman DA, et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Ped Infect Dis J 1994; 13: 792.CrossRefGoogle Scholar
  57. 57.
    Tristram DA, Welliver RC, Hogerman DA, et al. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement. Vaccine 1994; 12: 551.PubMedCrossRefGoogle Scholar
  58. 58.
    Belshe RB, Anderson EL, Walsh EE. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 1993; 168: 1024–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Pringle CR, Filipiuk AH, Robinson BS, et al Immunogenicity and pathogenicity of a triple temperature-sensitive modifed respiratory syncytial virus in adult volunteers. Vaccine 1993; 11: 473–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • John Mills

There are no affiliations available

Personalised recommendations